Rationale for off-label treatments use in primary progressive multiple sclerosis: A review of the literature

CONCLUSION: The literature lacks dedicated studies to support the off-label use of these disease-modifying therapies in PPMS. However, some limited data are available in the literature suggesting that the use of rituximab and cyclophosphamide could potentially be of some interest in specific subpopulations.PMID:35851485 | DOI:10.1016/j.neurol.2022.02.461

Source: Revue Neurologique - July 19, 2022 Category: Neurology Authors: T Chedid X Moisset P Clavelou Source Type: research